Tamoxifen
None
Technical catalog description
Tamoxifen is a selective estrogen receptor modulator (SERM) primarily used for PCT and prevention/treatment of gynecomastia. It works by blocking estrogen receptors in breast tissue while allowing estrogen to function normally in other tissues like bone and liver.
As a PCT medication, tamoxifen stimulates the release of LH and FSH from the pituitary gland, helping to restart natural testosterone production after a steroid cycle. It’s generally preferred over Clomiphene for most users due to fewer mood-related side effects and better tolerance.
Read next
Mechanism details
Tamoxifen (Nolvadex) is a SERM, selective estrogen receptor modulator. It does not lower estrogen levels in the blood. It blocks estrogen receptor activation at specific tissues, primarily breast tissue. This distinction is critical: someone running tamoxifen during cycle has not reduced their estrogen; they have blocked estrogen from binding at the breast while estrogen continues to act elsewhere, including at tissues where estrogen has positive effects (bone, cardiovascular, libido, mood).
This makes tamoxifen the preferred tool for protecting against gynecomastia specifically, without the systemic estrogen suppression risks of aromatase inhibitors. Users who find they are sensitive to gynecomastia even at moderate estrogen levels often run low-dose tamoxifen during cycle rather than over-suppressing estrogen with an AI.
In PCT, tamoxifen’s mechanism works differently: by blocking the estrogen receptor at the hypothalamus and pituitary, it removes the estrogen feedback signal that suppresses LH and FSH output. With that brake removed, LH and FSH rise, stimulating testicular testosterone production. The HPTA begins to restart. This is the foundation of most PCT protocols.
Hot flashes, nausea, mood changes, and reduced libido in some users
Rare but real clotting risk, especially in higher-risk patients
Total testosterone, LH, and FSH if used for PCT
Symptoms of clotting risk and intolerance
History of blood clots or major clotting risk without physician input
Using it as the main estrogen-control tool when aromatization is the real issue
Tamoxifen is the backbone of PCT for most users because it is well-studied, well-tolerated by most people, and directly addresses the HPTA restart goal. It is also the preferred on-cycle tool for breast tissue protection in users who want targeted gynecomastia prevention without systemic estrogen crash.
A reported half-life does not establish an administration schedule. No cycle-related frequency is validated in this catalog.
No PCT duration, recovery timetable, or follow-up laboratory interval is validated in this profile.
For on-cycle gynecomastia prevention: protection is active within the first week of use.
Using tamoxifen to manage estrogenic side effects that are not breast-specific, like water retention, mood changes, or libido issues during cycle. These require estrogen control (an AI), not receptor blocking. Tamoxifen does not help them.
Choosing a starting amount or escalating it from a generic PCT template. This profile does not establish either amount.
Running tamoxifen long-term on TRT without a clear indication. Chronic SERM use has its own hormonal and tissue-level consequences.
Community discussions compare tamoxifen and Clomiphene for recovery. This catalog does not validate a SERM amount, combination, or treatment duration.
Compared with Arimidex or Aromasin, tamoxifen answers a different question. AIs lower estrogen; tamoxifen blocks receptor activation. On-cycle, users choose between them based on whether they want to reduce circulating estrogen or just protect breast tissue while maintaining higher estrogen elsewhere.